195 related articles for article (PubMed ID: 26098893)
1. A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus.
Stewart-Jones GB; Thomas PV; Chen M; Druz A; Joyce MG; Kong WP; Sastry M; Soto C; Yang Y; Zhang B; Chen L; Chuang GY; Georgiev IS; McLellan JS; Srivatsan S; Zhou T; Baxa U; Mascola JR; Graham BS; Kwong PD
PLoS One; 2015; 10(6):e0128779. PubMed ID: 26098893
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus.
Boyington JC; Joyce MG; Sastry M; Stewart-Jones GB; Chen M; Kong WP; Ngwuta JO; Thomas PV; Tsybovsky Y; Yang Y; Zhang B; Chen L; Druz A; Georgiev IS; Ko K; Zhou T; Mascola JR; Graham BS; Kwong PD
PLoS One; 2016; 11(7):e0159709. PubMed ID: 27463224
[TBL] [Abstract][Full Text] [Related]
3. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
[TBL] [Abstract][Full Text] [Related]
4. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
[TBL] [Abstract][Full Text] [Related]
5. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
[TBL] [Abstract][Full Text] [Related]
6. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
[TBL] [Abstract][Full Text] [Related]
7. Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.
McGinnes Cullen L; Schmidt MR; Kenward SA; Woodland RT; Morrison TG
J Virol; 2015 Jul; 89(13):6835-47. PubMed ID: 25903340
[TBL] [Abstract][Full Text] [Related]
8. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.
Wiegand MA; Gori-Savellini G; Gandolfo C; Papa G; Kaufmann C; Felder E; Ginori A; Disanto MG; Spina D; Cusi MG
J Virol; 2017 May; 91(10):. PubMed ID: 28250126
[TBL] [Abstract][Full Text] [Related]
9. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
[TBL] [Abstract][Full Text] [Related]
10. Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.
Kwon YM; Lee Y; Kim KH; Jung YJ; Li Z; Jeeva S; Lee S; Moore ML; Kang SM
Vaccine; 2019 Oct; 37(44):6656-6664. PubMed ID: 31542260
[TBL] [Abstract][Full Text] [Related]
11. Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus.
Sastry M; Zhang B; Chen M; Joyce MG; Kong WP; Chuang GY; Ko K; Kumar A; Silacci C; Thom M; Salazar AM; Corti D; Lanzavecchia A; Taylor G; Mascola JR; Graham BS; Kwong PD
PLoS One; 2017; 12(10):e0186854. PubMed ID: 29073183
[TBL] [Abstract][Full Text] [Related]
12. Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV.
Steff AM; Monroe J; Friedrich K; Chandramouli S; Nguyen TL; Tian S; Vandepaer S; Toussaint JF; Carfi A
Nat Commun; 2017 Oct; 8(1):1085. PubMed ID: 29057917
[TBL] [Abstract][Full Text] [Related]
13. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
[TBL] [Abstract][Full Text] [Related]
14. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
[TBL] [Abstract][Full Text] [Related]
15. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
[TBL] [Abstract][Full Text] [Related]
16. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism.
Krarup A; Truan D; Furmanova-Hollenstein P; Bogaert L; Bouchier P; Bisschop IJM; Widjojoatmodjo MN; Zahn R; Schuitemaker H; McLellan JS; Langedijk JPM
Nat Commun; 2015 Sep; 6():8143. PubMed ID: 26333350
[TBL] [Abstract][Full Text] [Related]
17. A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain.
Swanson KA; Rainho-Tomko JN; Williams ZP; Lanza L; Peredelchuk M; Kishko M; Pavot V; Alamares-Sapuay J; Adhikarla H; Gupta S; Chivukula S; Gallichan S; Zhang L; Jackson N; Yoon H; Edwards D; Wei CJ; Nabel GJ
Sci Immunol; 2020 May; 5(47):. PubMed ID: 32358170
[TBL] [Abstract][Full Text] [Related]
18. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
[TBL] [Abstract][Full Text] [Related]
19. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.
Palomo C; Mas V; Thom M; Vázquez M; Cano O; Terrón MC; Luque D; Taylor G; Melero JA
J Virol; 2016 Jun; 90(11):5485-5498. PubMed ID: 27009962
[TBL] [Abstract][Full Text] [Related]
20. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
